

June 19, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref : Our letter dated July 30, 2025.

We refer to our letter dated July 30, 2025 informing that Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, entered into a definitive agreement with LANNETT SELLER HOLDCO, INC under which Aurobindo Pharma USA Inc will acquire 100% of membership interest in Lannett Company LLC from LANNETT SELLER HOLDCO, INC.

In this regard, we are pleased to inform you that the necessary approval from US Federal Trade Commission (FTC) for the acquisition of the Lannett business has been obtained today.

We anticipate that the transaction will close before the end of this month and will keep the exchanges informed if any future developments in this matter.

Please take the above information on record.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com